Gumokimab

Summary

Gumokimab (CHEMBL5095302) is a phase-3 clinical-stage antibody; indicated across 2 conditions including ankylosing spondylitis and psoriasis.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Antibody
• Indications: 2 conditions
• Clinical trials: 7

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL5095302
Name	Gumokimab
Type	Antibody
Max phase	3

Also known as: AK-111, AK111, Gumokimab, GUMOKIMAB

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
ankylosing spondylitis	3	MONDO:0005306	EFO:0003898
psoriasis	3	MONDO:0005083	EFO:0000676

Clinical trials

Total trials: 7.

Phase distribution

Phase	Trials
PHASE2	3
PHASE3	2
PHASE1	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06066125	PHASE3	COMPLETED	A Study to Evaluate the Efficacy and Safety of AK111 in Subjects With Moderate to Severe Plaque Psoriasis
NCT06378697	PHASE3	COMPLETED	A Phase III Study to Evaluate the Efficacy and Safety of AK111 in Subjects With Active Ankylosing Spondylitis
NCT05096364	PHASE2	COMPLETED	A Phase 2 Study of Efficacy and Safety of AK111 in Subjects With Moderate-to-Severe Psoriasis
NCT05467995	PHASE2	COMPLETED	A Study to Evaluate the Efficacy and Safety of AK111 in Subjects With Active Ankylosing Spondylitis
NCT06061471	PHASE2	COMPLETED	To Evaluate the Efficacy and Safety of AK111 Injection in the Treatment of Moderate to Severe Plaque Psoriasis
NCT06947109	PHASE1	NOT_YET_RECRUITING	A Clinical Study of AK139 in Healthy Subjects
NCT05504317	PHASE1	COMPLETED	A Study of AK111 in Subjects With Moderate-to-severe Plaque Psoriasis

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).